HealthTree Logo
search more_vert
close
person Sign In / Create Account
Know Your Myeloma Immunotherapy: Bispecific Antibodies with Dr. Cesar Rodriguez
Know Your Myeloma Immunotherapy: Bispecific Antibodies with Dr. Cesar Rodriguez image
Immunotherapy (CAR T, Bispecifics and more) Treatment
event Jun 23, 2022 / 07:00PM - 08:00PM EDT

Event Description

Bispecific antibodies have the potential to change myeloma treatment forever. Get to know this exciting immunotherapy. There are many bispecific antibodies being tested in clinical trials and awaiting FDA approval. What are some of their mechanisms of action? What is their potential in treating myeloma? Come with your questions and learn with us.

Schedule & Agenda

person
Introduction
07:00PM
Audrey Burton-Bethkee
Audrey introduces the agenda of the event and featured speaker Dr. Cesar Rodriguez.
person
Presentation
07:05PM
Dr. Cesar Rodriguez
Dr. Rodriguez talks about how bispecific antibodies have the potential to change myeloma treatment forever.
person
Questions and Answers
07:35PM
Audience
Type your questions in the chat and we will answer them!

Speakers & Moderators

The panelist Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio
The panelist Cesar Rodriguez, MD
Cesar Rodriguez, MD

Cesar Rodriguez, MD, recently joined the faculty of Mount Sinai Hospital and is the Clinical and Operations Director of the Myeloma Program for the system. He previously was Associate Professor of Hematology and Oncology at the Wake Forest School of Medicine and led the Myeloma program there for 6 years. His focus is early phase clinical trials, translational medicine using 3D culture models, and immunotherapies. He has led a number of first-in-human studies with bi-specific therapies and has opened the first tri-specific therapy for myeloma targeting NK cells. He is one of three winners of the second Myeloma Crowd Research Initiative (MCRI) competition. His project uses a three-dimensional organoid tumor modeling platform which allows the testing of multiple treatment combinations against a specific tumor to identify which treatments will work best for each individual’s type of myeloma. This personalized approach may help doctors to help find useful drug combinations that will have the most impact and avoid treatments that will be ineffective. Dr. Rodriguez earned his MD at Escuela de Medicina Ignacio A. Santos, Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, Mexico. He completed his residency at Texas Tech University Health Sciences Center at El Paso and a fellowship at the University of Louisville.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
GSK
Regeneron
Bristol Myers Squibb

Follow Us

facebook twitter